Logo Prima Biomed

Leadership Team

Marc VoigtChief Executive Officer

Mr. Voigt has served as our Chief Financial Officer and Chief Business Officer since 2012 and was appointed as CEO and Executive Director in July 2014. He has extensive experience in the corporate and biotechnology sectors. He joined Prima BioMed’s management team in 2011 as the General Manager of our European operations at Prima BioMed GmbH, where he currently serves as the Managing Director. He has previously worked as an investment manager for Allianz Insurance biotech venture fund, and as a personal assistant to a member of the Executive Board of Allianz Insurance. Mr. Voigt has also worked for German investment bank, net.IPO.AG, in the area of business development and German securities offerings. In the biotech sector, he has held the positions of CFO/CBO at Revotar Biopharmaceuticals AG and Medical Enzymes AG. He has a Masters Degree in Business Administration from the Freie Universität of Berlin, and is a member of the pharma licensing club Germany and a member of the judging panel of Germany’s largest business plan competition.

Frédéric Triebel, MD Ph.D.Chief Scientific Officer & Chief Medical Officer

Dr Triebel is our Chief Scientific Officer and Chief Medical Officer and has been with Prima BioMed since December 2014, following the completion of the acquisition of Immutep. Dr Triebel was the scientific founder of Immutep S.A. (2001) and served as the Scientific and Medical Director at Immutep from 2004. Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer center in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical hematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 144 publications and 16 patents.

Deanne MillerChief Operating Officer, General Counsel & Company Secretary

Ms. Miller joined Prima BioMed as General Counsel and Company Secretary in October 2012 and was promoted to the role of Chief Operating Officer in November 2016. She has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws (Honours) and Bachelor of Commerce, Accounting and Finance (double major) from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.

Christian MuellerDirector Clinical Development

Christian Mueller, MSc BBA, works in the field of clinical development of oncology drugs for more than a decade.

After finishing his studies at the Technical University Berlin with the Master of Science in Biotechnology he joined Medical Enzymes AG who has its focus on therapeutic enzymes for the treatment of cancer. As a project manager he was responsible for all deliverables of clinical phase I and II studies. Later he built up a clinical team and took over the responsibilities for the strategic clinical development of the lead compound. Since 2012 he worked with Ganymed Pharmaceuticals AG. Ganymed is developing ideal monoclonal antibodies in the field of immune oncology. As a Manager Clinical Research he was responsible for the clinical development program of the lead antibody and the setup and management of the clinical team. Most recently he successfully completed a multinational randomized phase II study with 200+ patients investigating the lead antibody as first line treatment in combination with chemotherapy in patients with advanced metastatic gastric cancer (publication during ASCO 2016). His efforts in the field of clinical development have led to several publications and patents.

Claudia Jacoby, Ph.D.Director Manufacturing

With more than 15 years of experience in the biotech industry, Dr Jacoby joined Prima BioMed Ltd. in 2015. Prior to her current role, she held various positions at pre-clinical and clinical-stage pharmaceutical companies, where she gained comprehensive experience in protein expression and purification as well as in analytical and preclinical development. As Head Biochemist and Head of Manufacturing at an European biotech company, she developed and supervised manufacturing processes conducted according to "Good Manufacturing Practice" (GMP) of biologicals and small molecules in interaction with Contract Manufacturing Organisations ensuring the supply of clinical trials up to Phase II.

In parallel Dr Jacoby was acting as an independent Medical Writer supporting companies in regulatory interactions for clinical trial applications.

Dr Jacoby has a Master degree in Biochemistry and completed her PhD at the Institute for Biotechnology of the Martin-Luther-University of Halle-Wittenberg, Germany.

Jay R. Campbell Vice President, Business Development and Investor Relations

Jay Campbell joined Prima in February 2017 and was previously Senior Director of Business Development and Investor Relations at Kolltan Pharmaceuticals, Inc., a privately-held biotechnology company developing biologic therapeutics targeting receptor tyrosine kinases for oncology and immunology, which was acquired by Celldex Therapeutics, Inc. in November 2016.

Prior to Kolltan, Mr. Campbell spent over 13 years working in the financial services industry and as an independent business development consultant, the majority of which was as an investment banker focusing on the life sciences industry. During this time, Jay was a business development consultant to ISTA Pharmaceuticals, Inc. in connection with the company’s review of strategic alternatives that culminated in the sale of the company to Bausch & Lomb in 2012. Mr. Campbell previously worked at Maxim Group, Royal Bank of Scotland, ABN AMRO, Rothschild, and Schroders. Throughout his career, Jay has successfully worked on 25 financing, licensing, and M&A transactions representing more than $13.0 billion. Jay also serves as a member of the board of directors of Update Pharma, Inc., a privately held clinical-stage small molecule company focused on developing overlooked or underutilized anti-cancer drugs.